Effects of the COVID-19 Pandemic on Anti-vascular Endothelial Growth Factor Treatment in China

• Main Authors: Kai-Bo Yang, Hao Feng, Han Zhang
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2020-12-01
• Series: Frontiers in Medicine
• Subjects: COVID-19; anti-VEGF (vascular endothelial growth factor); age-related macula degeneration (AMD); retinal vein occlusion (RVO); diabetic macular edema (DME)
• Online Access: https://www.frontiersin.org/articles/10.3389/fmed.2020.576275/full

We evaluated the impact of the COVID-19 pandemic on anti-VEGF treatment in ophthalmology patients in a single hospital in northern China. A total of 93 anti-VEGF injections were administered to 85 eyes of 72 patients at The China Medical University First Hospital Department of Ophthalmology during the COVID-19 pandemic. Compared to the same period in 2019, the number of injections decreased by 70%. Fifty-nine eyes of 46 patients were receiving 3+PRN anti-VEGF treatment prior to the outbreak of the COVID-19 pandemic; all of these patients experienced treatment interruptions due to COVID-19-associated reasons. Anatomic and functional outcomes suggest that patients with anti-VEGF treatment interruptions are at risk for severe adverse visual sequelae. Moreover, deferred anti-VEGF treatment due to patient-related or department-related reasons during the COVID-19 pandemic may result in poor visual outcomes for new patients. Our results suggest that COVID-19 has had a significant negative effect on anti-VEGF treatment in ophthalmology patients. Detailed guidance from global experts in ophthalmology is highly sought after in these challenging circumstances.